GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Greenwich Lifesciences Inc (GLSI) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising clinical trial results that could potentially double the market for its GLSI-100 product, the stock lacks immediate positive trading signals, and its financial performance remains weak with no revenue and negative net income. The technical indicators suggest a neutral to slightly bearish trend, and there is no recent news or significant trading activity to act as a catalyst. A hold position is recommended until stronger entry signals or financial improvements emerge.
The MACD is negative and expanding (-0.198), indicating bearish momentum. RSI is neutral at 43.73, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 26.828, with key support at 24.384 and resistance at 29.273. Overall, the technical indicators suggest a neutral to slightly bearish trend.
H.C. Wainwright raised the price target to $50 from $39, citing positive Phase 3 trial results for GLSI-100, which reduced breast cancer recurrence by 80% in a specific patient group. This could potentially double the market for the product.
The stock experienced a -2.50% regular market decline and a -1.69% pre-market drop, indicating weak short-term sentiment. Financial performance remains poor with no revenue and negative net income. Technical indicators do not show bullish momentum.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income of -$4,151,845 (improved by 55.57% YoY), and an EPS of -0.3 (improved by 50% YoY). Gross margin remains at 0%. Overall, the company is not yet profitable and has no revenue.
H.C. Wainwright maintains a Buy rating and raised the price target to $50 from $39, citing encouraging clinical trial results. This reflects optimism about the company's future potential but is contingent on successful commercialization of GLSI-100.
